<DOC>
	<DOCNO>NCT00357682</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use esomeprazole aspirin may prevent esophageal cancer patient Barrett 's metaplasia . It yet know whether esomeprazole effective without aspirin prevent esophageal cancer patient Barrett 's metaplasia . PURPOSE : This randomized phase III trial study esomeprazole without aspirin compare well work prevent esophageal cancer patient Barrett 's metaplasia .</brief_summary>
	<brief_title>A Phase III , Randomized , Study Aspirin Esomeprazole Chemoprevention Barrett 's Metaplasia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES - To assess whether intervention aspirin result decrease rate cause mortality conversion rate Barrett 's metaplasia adenocarcinoma high grade dysplasia . - To assess whether high dose PPI ( protein pump inhibitor ) therapy result decrease rate cause mortality conversion rate Barrett 's metaplasia adenocarcinoma high grade dysplasia . SECONDARY OBJECTIVES - To assess whether intervention aspirin result decrease high-grade dysplasia , decrease cause mortality , decreased oesophageal cancer incidence decrease cause-specific mortality consider separately - To assess whether intervention high dose PPI result decrease high-grade dysplasia , decrease cause mortality , decreased oesophageal cancer incidence decrease cause-specific mortality consider separately - To assess whether clinical molecular risk factor identify BM ( Barrett 's Metaplasia ) development BA . - To assess cost effectiveness aspirin and/or PPI treatment prevention BA . - To assess whether intervention PPI and/or aspirin induces change expression molecular marker BA . - To investigate new gene important progression BA , unique tissue bank available complete endoscopic , histological , physiology pharmaceutical history . - To assess inherited genetic factor predisposition oesophagitis BM , BM , LGD HGD BA . - To assess biological risk factor cardiac disease aspirin resistance . - To assess gender difference outcomes . Cancer Research UK approve study 2003 10 year period run 1st January 2005 31st December 2014 . Funding renewable annually dependent satisfactory review independent committee . An application funding extension make CRUK 18 month end current grant . A total 2513 patient accrue study . They remain trial medication follow .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Aged ≥18 year . 2 . Circumferential Barrett 's metaplasia least 1cm length ( ≥C1M1 ) tongue Barrett 's metaplasia least 2cm length ( ≥C0M2 ) ( irrespective presence historically histologically proven intestinal metaplasia ) . 3 . Able give write informed consent . 4. WHO performance status 0 1 i.e . fully active selfcaring . EXCLUSION CRITERIA 1 . High grade dysplasia carcinoma enrolment . 2 . Medical condition would make complete endoscopy complete trial difficult include : 1 . Frequent transient ischaemic attack ( 3 ) severe cerebral vascular accident previous 6 months* 2 . Severe respiratory disease arterial oxygen saturation le 90 % rest 3 . Severe ischaemic heart disease ( exercise tolerance le 100 yard life expectancy &lt; 4 year ) myocardial infarction previous 3 month 4 . Severe inflammatory bowel disease require least one hospital admission 5 day last year bowel open &gt; 6 times/day * Patients answer yes criterion a. eligible PPIonly ( nonaspirin ) arm trial 3 . Continuous/frequent nonsteroidal antiinflammatory drug use COX2 inhibitor ( 60 day per year total ) . 4 . Patients absolute contraindication PPIs , aspirin excipients i.e . allergy , ulcer , renal impairment use oral anticoagulant . 5 . Pregnant lactate woman undergo endoscopy may give dispensation stop drug therapy year . This discussed Trial Office . If patient suitable inclusion later become unsuitable discussed Trial Office withdrawn . Only exceptional circumstance patient follow i.e . withdrawal consent current life threaten disease poor outcome therefore unable tolerate endoscopy . In circumstance patient follow outpatient clinic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>Barrett 's esophagus</keyword>
</DOC>